Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
May 16, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
May 14, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc Reports First Quarter 2024 Financial Results
May 02, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
April 29, 2024 16:50 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
April 16, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
March 05, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
February 13, 2024 16:30 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024 16:15 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
January 18, 2024 17:00 ET
|
Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
January 04, 2024 16:45 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...